Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?

Similar documents
When should you treat blood pressure in the young?

Central Pressures and Prehypertension

How clinically important are the results of the large trials in hypertension?

Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις

HTA ET DIALYSE DR ALAIN GUERIN

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Hypertension Update Clinical Controversies Regarding Age and Race

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Early Detection of Damaged Organ

Hypertension Update 2009

Managing HTN in the Elderly: How Low to Go

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Antihypertensive Trial Design ALLHAT

Egyptian Hypertension Guidelines

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Slide notes: References:

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Background. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Arterial Pressure in CKD5 - ESRD Population Gérard M. London

Update in Hypertension

Cardiovascular Diseases in CKD

THE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

The monthly ESH guide through publications

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Arterial function and longevity Focus on the aorta

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France

Endothelial function is impaired in women who had pre-eclampsia

Treating Hypertension in Individuals with Diabetes

Blood Pressure Targets in Diabetes

Management of Hypertension

INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

47 Hypertension in Elderly

Hypertension in Aortic Valve Disease

ADVANCES IN MANAGEMENT OF HYPERTENSION

An Epidemiological Overview

Hypertension Pharmacotherapy: A Practical Approach

Preventing Early Vascular Ageing (EVA) and its hemodynamic changes

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Long-Term Care Updates

D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

STANDARD treatment algorithm mmHg

Pharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University

Combination Therapy for Hypertension

Hypertension Management Controversies in the Elderly Patient

Treating Hypertension in 2018: What Makes the Most Sense Today?

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Preventing and Treating High Blood Pressure

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease

Causes of Poor BP control Rates

Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호

Coronary artery disease (CAD) risk factors

By Prof. Khaled El-Rabat

An Epidemiological Overview

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Update on Current Trends in Hypertension Management

ADVANCES IN MANAGEMENT OF HYPERTENSION

Supplement materials:

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Falls Assessment and Medication

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

Hypertension and Cardiovascular Disease

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia?

Modern Management of Hypertension

Objectives. Describe results and implications of recent landmark hypertension trials

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Abstract nr AHA, Chicago November European Heart Journal Cardiovascular Imaging, in press. Nr Peter Blomstrand

Hypertension Management Focus on new RAAS blocker. Disclosure

T. Suithichaiyakul Cardiomed Chula

Cedars Sinai Diabetes. Michael A. Weber

Improving risk prediction focusing on intermediate endpoints. Arterial stiffness. Pr. Stéphane LAURENT, MD, PhD, FESC

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

How do we diagnose hypertension today? Presentation Subtitle

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Which CVS risk reduction strategy fits better to carotid US findings?

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra

Prevention of Heart Failure: What s New with Hypertension

Transcription:

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia

Percieved risk

Actual risk

Sehestedt et al, European Heart Journal 2010 Risk prediction is improved by adding markers of sublinical organ damage to SCORE

Stratification of total CV risk Further emphasis has been given to identification of organ damage, since hypertension-related asymptomatic alterations in several organs indicate progression in the CVD continuum, which markedly increases the risk beyond that caused by the simple presence of risk factors 2013 ESH/ESC Guidelines for the management of arterial hypertension

Evaluation of the elderly patient with known or suspected hypertension must accurately determine BP, and if elevated: 1) identify reversible and/or treatable causes; 2) evaluate for organ damage; 3) assess for other CVD risk factors/comorbid conditions affecting prognosis; and 4) identify barriers to treatment adherence. JACC 2014

Journal of Hypertension 2010 * p<0.01 100 80 60 40 41 Low * Moderate * * High * 6 10 14 31 36 37 33 23 20 59 58 53 53 46 0 Routine + echocardiography + renal TOD + PWV + carotid ultrasound

Factors - other than office BP - influencing prognosis used for stratification of total CV risk (2) 2013 ESH/ESC Guidelines for the management of arterial hypertension

Search for asymptomatic organ damage - Kidney 2013 ESH/ESC Guidelines for the management of arterial hypertension

(incidence rate ratio) Hunt II Study, Arch Intern Med. 2007 9709 participants of the second Nord-Trøndelag Health Study (HUNT II), a Norwegian community-based health study, followed for 8.3 years with a 71% participation rate Cardiovascular mortality risk

The combined variable improved cardiovascular risk stratification at all age levels, but particularly in elderly persons where the predictive power of traditional risk factors is attenuated... Arch Intern Med. 2007

European Heart Journal 2007 Prospective study of 70-year-old men free from HF at baseline (Uppsala Longitudinal Study of Adult Men coho Cutoff: UAER median value, 4.7 mg/min In Cox proportional hazards models adjusted for established and novel risk factors for HF, a 1 SD increase in log UAER increased the risk of HF in individuals without anti hypertensive treatment (hazard ratio 1.49; 95% CI 1.13 1.98; p < 0.005)

Search for asymptomatic organ damage - Arteries 2013 ESH/ESC Guidelines for the management of arterial hypertension

A man is as old as his arteries Thomas Sydenham, 1624 1689

Mannheim Carotid Intima-Media Thickness Consensus Update (2004 2006) Cerebrovascular Disease 2007; ;23:75 80 plaque and IMT measurement according to Mannheim consensus. 1: thickness > 1.5 mm 2: lumen encroaching > 0.5 mm; 3, 4: > 50% of the surrounding IMT value

Unadjusted Cumulative Event-free Rates for the Combined End Point of Myocardial Infarction or Stroke, According to Quintile of Combined Intima-Media Thickness 5858 subjects 65 years of age or older, follow-up period of 6.2 years NEJM 1999, D.H. O Leary et al.

1289 men aged 60 to 74 years without a previous stroke or CHD Incidence of stroke Men with a plaque in the ICA had a 3-fold higher risk of stroke than those without The combination a plaque, of CCA and internal the carotid plaque artery (ICA) surface wall thickness irregularity was a further better predictor of the risk of stroke than was CCA wall thickness alone. increased the stroke risk. A significant excess risk of stroke was confined to men with an uncalcified plaque. Stroke 2004

DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) DBP (mm Hg) DBP (mm Hg) SBP (mm Hg) SBP (mm Hg) Mean Systolic and Diastolic BP by Age and Race/Ethnicity for Men and Women (US Population ³Age 18 Years, NHANES III) 150 150 130 130 110 80 Non-Hispanic Black Non-Hispanic White Mexican American 110 80 70 70 0 0 150 150 130 130 110 Pulse pressure 110 Pulse pressure 80 80 70 70 0 18-29 30-39 40-49 50-59 60-69 70-79 80+ Men, Age (y) 0 18-29 30-39 40-49 50-59 60-69 70-79 80+ Women, Age (y) Burt VI, et al. Hypertension. 1995;25:305-313.

Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE

Compliance function of large arteries Arterial compliance Arterial compliance Left Ventricl e Peripheral resistances Left Ventricl e Peripheral resistances SYSTOLE DIASTOLE

Carotid-femoral pulse wave velocity DL dp PWV. Dt. V dv Dt L Carotid femoral PWV can be assimilated to aortic stiffness

Reference values for pulse wave velocity (PWV): mean values according to age and blood pressure categories (11 092 subjects) Reference Values for Arterial Stiffness' Collaboration. Eur Heart J 2010;31:2338-2350

A cohort of 141 subjects (mean age, 87.1±6.6 years), dementia in 63.8 %, was studied in 3 geriatrics departments in a Paris suburb. During the 30-month follow-up, 56 patients died (27 from CV events). Logistic regressions indicated that age (p=0.005) and a loss of autonomy (p=0.01) were the best predictors of overall mortality. For cardiovascular mortality, aortic PWV was the major risk predictor (P0.016). Arterioscler Thromb Vasc Biol. 2001

Reclassification indices showed that the addition of apwv improved risk prediction (13% for 10-year CVD risk for intermediate risk). Ben Shlomo B et al, JACC 2014

Ben Shlomo et al, JACC 2014

280 eighty older subjects with subjective complaints of memory loss and no previous stroke (age 78.3±6.3 yrs) Interpretation: Systemic hemodynamic parameters (higher PWV and hypotension) together with cerebral microvascular damage (WML) are significantly associated with poorer cognitive function and may identify older subjects with subjective complaints of memory loss at higher risk of cognitive decline. International Journal of Cardiology 2013

Hypertension 2013; 61:130-136

Hypertension 2014

Correlation between PWV and LV structure Studio Vobarno, Clinica Medica, Università di Brescia

Search for asymptomatic organ damage - Heart 2013 ESH/ESC Guidelines for the management of arterial hypertension

Increase in wall thickness with age in healthy men and women Bronx Longitudinal Study Aging Prevalence of concentric LV geometry increases with agenormalized RWT Values age-normalized RWTm = 0.41 RWTp = 0.40 Gerstenblith G et al. Circulation. 1977;56: 273 278. de Simone G et al Hypertension. 2005;45:64-68

Prevalenza Disfunzione Diastolica (Criteri Primari) 60 % 50 p < 0.001 40 30 p = 0.003 p = 0.023 p = 0.008 p < 0.001 20 10 0 Tutti M F C NC No Sì Controllo PA Sindrome Metabolica 65-70 > 70-75 > 75-80 > 80 < 130 130-139 140-149 150-159 160 Età PAS Zanchetti et al., J Hypertens 2007; 25: 2158 2167

LVH and CV Risk in Different Populations LVH diagnosed by echocardiography is a powerful predictor of myocardial infarction, stroke and CV death in: Apparently uncomplicated hypertensive patients In subjects with or without angiographic coronary heart disease In patients with previous myocardial infarction In subjects from general populations in epidemiological studies It has been estimated that 1g/m2 increase in LVMI is associated with a 1-2 % increase in the risk of CV events

Myocytes Cardiomyocite changes Hypertrophy Cell loss (apoptosis) Functional changes Systolic Dysfunction Pressure Overload Extracellular matrix Collagen network changes Reactive fibrosis Replacement fibrosis HF 26/01/2015 02:09:55 Vascular Compartment Coronary disease Microcirculation changes Capillary rarefaction Diastolic Dysfunction

LV mass and incident heart failure The Cardiovascular Health Study Quartiles of echocardiographic LVM/BSA (g/m2): < 67.7, 67.8 to 79.2, 79.3 to 93.5, and > 93.5. Drazner et al. JACC 2004; 43 :2207 15

In multivariable logistic regression models, including age, sex, BP levels, and use of antihypertensive drugs as covariates, the highest LVMI was found to be independently associated with a two-fold higher likelihood of having dementia. The association persisted significant even after adjustment for arterial stiffness

Sensitivity to detect treatment-induced changes, time to change and prognostic value of change by markers of asymptomatic OD 2013 ESH/ESC Guidelines for the management of arterial hypertension

VOBARNO Study 478 subjects (age range 43-74 years) 40% elderly (193 subjects) 100 90 80 70 60 50 40 30 20 10 0 % Prevalence of hypertension 53 Non elderly Χ 2 <0.001 86 Elderly Clinica Medica, University of Brescia % % 100 90 80 70 60 50 40 30 20 10 0 20 18 16 14 12 10 8 6 4 2 0 Uncontrolled hypertension Χ 2 <0.001 78 45 Non elderly Elderly Resistant hypertension Χ 2 <0.001 14 1 Non elderly Elderly

Prevalence of OD 35 Prevalence of LVH % 30 25 20 15 31,1 10 5 0 8,1 Non elderly Elderly Studio Vobarno, Clinica Medica, Università di Brescia

Prevalence of OD Prevalence of IMT or plaques Prevalence of PWV>10 m/s 120 80 % 100 80 60 40 20 0 64,2 Non elderly 95,9 Elderly % 70 60 50 40 30 20 10 0 21,1 Non elderly 68,5 Elderly Studio Vobarno, Clinica Medica, Università di Brescia

Grazie per l attenzione

8.4: Continued search for asymptomatic organ damage On the whole, it appears reasonable to search for at least some asymptomatic OD, not only for the initial stratification of CV risk, but also during follow-up 2013 ESH/ESC Guidelines for the management of arterial hypertension

0 BB VS OTHER DRUGS 31 paired comparisons 2680 pts 0 ARB VS OTHER DRUGS 20 paired comparisons 2384 pts -2-2 -4-4 -6-6 -8-8 -10-12 -14 BB -8,8 Other drugs * -11,6-10 -12-14 * -12,6-9,4 ARB Other drugs * p<0.01 Pairwise Comparison of Each Drug Class With the Other Classes Statistically Combined Fagard et al, Hypertension 2009

Treatment Age Years Treatment Duration N pts Change in LVM % Change in SBP mmhg Terpstra W et al 2000 ELVERA Lisinopril 60-75 2 years 85-23.7% -26 Amlodipine 81-23.6 % - 26.5 Schulman S et al 1990 Verapamil > 60 years 6 months 21-18 % -28 atenolol 21 + 3 % -32 Dahlof et al 2004 LIFE Losartan 55-80 years 6 months 479-17.4 % -30 Mean age Atenolol 481-14.4 % - 27 67 yrs

Comparative effect of antihypertensive drugs on aortic stiffness, wave reflection and central PP Aortic PWV Central PP, Augmentation index ACE-Inhibitors Angiotensin Receptor Blockers Calcium channel blockers Thiazide diuretics Vasodilating β-blockers Non vasodilating β-blockers

22 trials published between 1996 and 2005: - 8 trials antihypertensive drugs vs placebo or no-treatment - 9 trials new with old drug classes - 5 trials ACE inhibitors and CCBs Conclusions: Calcium channel blockers reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke. Stroke online June 8, 2006